Last reviewed · How we verify
NCT04581655: ONCOTIPNET
ONCOTIPNET: Multicenter Study on Risk Factors and Outcome in Cancer Pediatric Patients Admitted in Italian PICUs
trial in Pediatric Cancer in 500 participants. Completed in 1 July 2022.
30 April 2022
Quick facts
| Lead sponsor | Azienda Ospedaliera di Padova |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 500 |
| Start date | 1 March 2021 |
| Primary completion | 30 April 2022 |
| Estimated completion | 1 July 2022 |
| Sites | 17 locations across Italy |
Conditions studied
- Pediatric Cancer — all drugs for Pediatric Cancer →
- Critically Ill — all drugs for Critically Ill →
Sponsor
Azienda Ospedaliera di Padova — full company profile →
Who can join
Under 18, any sex, with Pediatric Cancer or Critically Ill. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The study will describe characteristics of pediatric cancer patients admitted to Italian PICUs and will analyze risk factors of PICU admission, neurological outcome, and mortality. After a retrospective analysis (2019-2020), investigators will perform a prospective study over 12 months gathering data from 15-20 Italian PICUs.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Exploring risk factors for pediatric cancer patients admitted to the Pediatric Intensive Care Unit: insight from a multicenter observational study revealing no association with mechanical ventilation.
Amigoni A, Boscato S, Mondardini MC, Cavagnero F, et al · · 2025 · PMID 41088488 · DOI 10.1186/s44158-025-00275-6
Verify or expand the search:
- PubMed search for NCT04581655
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Pediatric Cancer
Currently open trials in the same condition.
- NCT07506239 — Efficacy of Laser Interstitial Thermal Therapy in Young Persons With Low-grade Glioma · NA · recruiting
- NCT07278778 — Cancer Care Companion · NA · recruiting
- NCT07473518 — Thyroid Carcinoma in Cancer Patients Undergoing Radiotherapy · recruiting
- NCT06939322 — LOG-I - Impact Study of LOG-AFTER Software on Long-term Monitoring of Former Patients (LOG-I - LOG-Impact Study) · NA · recruiting
- NCT07188311 — Pucotenlimab Combined With Lenvatinib and Chemotherapy in the Treatment of Advanced, Relapsed/Refractory Hepatoblastoma · NA · recruiting
Other Azienda Ospedaliera di Padova trials
Trials by the same sponsor.
- NCT07241676 — Early Recurrence After Surgery for Pancreatic Cancer · enrolling by invitation
- NCT07056972 — Surveillance Discontinuation in 5 Year Stable Trivial Branch Duct Intraductal Papillary Mucinous Neoplasms · not yet recruiting
- NCT07072143 — An International Study on Pediatric Patients With Rare Tumors. · recruiting
- NCT07241663 — Surgery for Locally Unresectable Pancreatic Cancer · recruiting
- NCT06720883 — Robotically Assisted Surgery For Perihilar Cholangiocarcinoma: A Prospective Study · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04581655 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Azienda Ospedaliera di Padova
- Last refreshed: 19 July 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04581655.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing